Member Info for travel_light

Is the claimant Microsoft after being associated with his Lordships timelines and his claim to use Excel spreadsheets to produce them ?

thanks for video link. Detailed but worth the time for anyone interested in how results are appraised.

shame this thread got hijacked. agree with OP

PL yeah that would be good feelings all round !

is that reported as public info at end phase 1 ?

thats the nice thing with speadsheets, update a bit of data, and you get a new timeline. Must save hours.

i'm hoping for some update about the direction 2022 will see the acrylic/wool fashion wear will take. Kinda thinking a multi layered, adaptable, mix and match vibe. Al is a trend setter.

other news, nah, cos that would be naughty to share without telling the existing share holders, and god forbid that AIM would allow that, or that Al would treat existing support so poorly.

hi I'll bite

it's pre-cision tech rather than affimers. Pre-cision is a tech that lets components activate in tumours due to higher concentration of FAP. Basically allows close targeting of tumours.

interesting press release although I think the Can.seek tech has some way to go yet.

https://www.pointbiopharma.com/our-products/pipeline

live here. Have to be honest, know more people who are +ve than ever before. Milder symptoms, and most people seem relaxed. No masks in shops etc. Advised to work from home. we get free pcr test delivered/colleccted to door, but they are now taking an age to process.

Sniffle Stick

Whoa was panicing a little there, thought Al had bought a summer cottage in Korea.

Still got the juices running better than a pint mug of mocha coffee.

@roundhowe thanks.

in follow up they seem keen:-)

https://www.investegate.co.uk/avacta-group-plc/rns/issue-of-equity/202102020830016886N/

does anyone have details of how Precisions is licensed by Avacta. What payments would be dues to Tuftts and Bach, if any ?

looking into the past I found https://www.thepharmaletter.com/article/avacta-rockets-as-it-inks-deal-with-bach-biosciences-tufts

it's a bit of an odd release as it mentions conjugate affimers but not FAP tech.

other releases it say licensed rather than jointly patented.

How would such a license work normally ?

https://avactaanimalhealth.com/

It’s mentioned in annual reports I think but is small beans.

Rb40, thanks for polite correction

Have to admit from text in RNS I had assumed small clinical trial was Spain and that lab tests had followed up due to some issues. That’s just an assumption, it’s not clear when issues where known, at least to me. I might be just being paranoid. :-)

Cheers TL

As reported on 15 December 2021, the AffiDX® SARS-CoV-2 antigen test has been shown to detect the Omicron variant of the SARS-CoV-2 virus in patient samples in a small clinical study. Whilst the AffiDX® antigen test is effective at identifying high viral loads of Omicron, further laboratory analysis…..

Errr
Fund raising
Saliva test
September RNS when likely knew about antibody issues

Given Spain partner would have released the data not sure he had a lot of choice. Same goes for fund raise, good move, but not exactly a straight bat given statements prior.

But yeah he’s pretty good at sugar coating bad news.

Normal growth curve if expected value materializes will attract new II.

No point waiting for the results, and then panic to maximize interest. Get II ahead of potential news curve. II have a lot of choice so start creating share demand.

The only thing I infer is that there isn’t known bad news coming.

I’m Confused. I’ve been studying the Greek
Alphabet harder than an future PM in detention. Now we have sub-variants with another naming convention …oh the horror.:-)

puggle, great friday question. Interesting to see other peoples thoughts. Snaps for Puggle !

my humble thoughts (yes I said humble).
I think valuation will change over time and depend on how many candidates for end product/cancers targeted and how they get thru trials. AVA6K is interesting thou, does the fact iDox is already our there change the valuation path. I am hoping it does.
2 year time frame 1B+, 4 year 4-6B+

Avacta also have a second/third Tx string to their bow of artificial antibody like action/interfering with how cancer cell hide from immune system. This will hopefully buffer bad news a bit, although given decline from 280, maybe not. They also have a bunch of partners working on solutions too, but they too may be a long time coming to market. Too little info to make strong case for higher SP than is there today, bad news from partner could be a kick in the nadgers, and a buying opportunity for case above.

so for TX, PL might be buying a massive ocean going yacht in 2024, he's promised us all a go, or it might be a quick trip in a park row boat with some Super Strength before joining Mr R down an alley for the night shift end of 2022.

https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/what-clinical-trials-are/phases-of-clinical-trials#:~:text=There%20are%203%20main%20phases,Some%20trials%20are%20randomised.

Hang about here, chew the fat, react only to real news, ignore everyone, try to annoy Marik and his alter egos.

for my own evaluation I consider Dx to be near 0. Not because of the tech but because the company has had over a decade to make some proper money and has failed despite a global testing crisis. It implies an inability to run a DX business. Doesn't make them bad, people, doesn't mean they don't work hard. Doesn't make me a bad person for having a different risk profile to DX then someone else. Be interesting if anyone here for short term DX gain (might happen, good luck if you are here for that, bigger spherical body parts than I have)

good question, insert thumb up emoji.

thanks. Anyone on this BB going, who could share impression of the meeting etc. Be cool to know.